Geron Corp (GERN): Depreciation & Amortization
$474.0K
Year ended 2025-12-31
$485.0K
Trailing 12 months to 2026-06-30
+18.1%
3-year compound annual growth
+24.6%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $474.0K | -13.2% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $546.0K | +23.5% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $442.0K | +53.5% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $288.0K | +34.0% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $215.0K | +36.1% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $158.0K | +146.9% | 2023-03-16, From 2020-01-01 |
| 2019-12-31 | $64.0K | n/a | 2022-03-10, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Geron Corp (GERN) | 2025-12-31 | $474.0K | -13.2% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $9.26M | -26.0% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $1.74M | +154.6% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $1.60M | +14.3% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $15.27M | +12.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $60.74M | +39.5% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $490.0K | +24.7% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $2.54M | -0.7% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $2.42M | +8.4% |
Compare GERN, LAB, NUVB, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗